|Sold to Teva Pharmaceuticals (July 2015)|
|Industry||Branded and generic pharmaceuticals, and pharmaceutical research and development.|
|Founded||Libertyville, Illinois, United States (Spring 1984)|
|Founder||Allen Chao, Ph.D. and David Hsia, Ph.D.|
|Headquarters||Dublin, Ireland and Parsippany-Troy Hills, New Jersey, United States.|
Number of locations
|40 manufacturing facilities, 27 global R&D centers and marketing/sales facilities worldwide.|
|Paul Bisaro, Executive Chairman, Brenton L. Saunders President and CEO|
|Products||Branded and generic pharmaceuticals|
|Revenue||US$ 13.062 billion(2014)|
|US$ 1.090 billion (2014)|
|-US$ 1.630 billion (2014)|
|Total assets||US$ 6.881 billion (2014)|
|Total equity||US$ 28.335 billion (2014)|
Number of employees
|21,600 (Feb. 2015)|
Actavis (formerly known as Watson Pharmaceuticals and Actavis, plc, prior to the acquisition of Allergan, inc) is a global pharmaceutical company focused on developing, manufacturing and commercializing branded pharmaceuticals, generic and over-the-counter medicines, and biologic products. Actavis has a commercial presence across approximately 100 countries. The company has global headquarters in Dublin, Ireland and administrative headquarters in Parsippany-Troy Hills, New Jersey, United States.
Actavis, plc markets a portfolio of brand products through six franchises in key therapeutic categories including: Aesthetics/Dermatology/Plastic Surgery; Neurosciences/CNS; Eye Care; Women’s Health and Urology; GI and Cystic Fibrosis; and Cardiovascular Disease and Infectious Disease. The company's product portfolio includes Botox, Namenda, Restasis, Linzess, Bystolic, Juvederm, Latisse, Lo Loestrin Fe, Estrace, Teflaro, Dalvance, Ozurdex, Optive, Natrelle, Viibryd, Liletta, Saphris, Enablex, Actonel, Androderm, Gelnique and others.
Actavis, plc also operates the world's third-largest generics business. The company is ranked in the top 3 in 12 global markets, the top 5 in 16 global markets, and in the top 10 in 33 global markets. Actavis also develops and out-licenses generic pharmaceutical products outside the U.S. through its Medis third-party business, the world's largest generic pharmaceutical out-licensing business. Medis has more than 300 customers globally, and offers a broad portfolio of more than 200 products. Actavis, plc is also developing biosimilars products in oncology and other therapeutic categories, and currently has a portfolio of five biosimilar products in development. Actavis, plc has more than 40 manufacturing and distribution facilities around the world, with a capacity of approximately 40 billion units annually. Actavis Global Operations also includes Anda, Inc., the fourth-largest U.S. generic pharmaceutical product distributor in the United States.
In July 2015, Allergan, Plc announced it would sell its Generics division of the company to Teva Pharmaceuticals for $40.5 billion, a transaction proposed for completion by the first quarter of 2016.
- 1 History
- 2 Company evolution
- 3 Locations and facilities
- 4 References
- 5 External links
The company was founded in the spring of 1983, when, with funding from friends and family, colleagues Allen Chao, Ph.D. and David Hsia, Ph.D., began a small drug development enterprise. Just two months later, the founders established an initial product development and analytical laboratory with six employees (including both founders) in a leased space in Libertyville, Illinois.
By late fall of the same year, the company moved to Southern California into an initial 2,000-square-foot (190 m2) leased facility in Corona, and the development and manufacturing of generic pharmaceuticals began. The Corona site became the corporate headquarters for the rapidly expanding U.S. company.
Throughout its history, Actavis has expanded both organically and as the result of strategic acquisitions that brought broader product lines, enhanced drug delivery technologies, and ultimately branded pharmaceutical products to the company. In 1993, Actavis, then Watson, announced its initial public offering (IPO) of shares of common stock. The company was initially listed on the NASDAQ under the ticker symbol WATS. The company moved to the New York Stock Exchange (NYSE) in 1997, and began trading under the symbol WPI.
2000 to 2009
In 2000, the company acquired Schein Pharmaceutical, Inc., an acquisition that more than doubled the company’s size. In that same year, the group reported revenues in excess of $1 billion. In the fall of 2006, it acquired Andrx Corporation, a Fort Lauderdale, FL–based pharmaceutical company, making it the third largest specialty pharmaceutical company based on total prescriptions dispensed. In 2007, Dr. Allen Chao retired as President and Chief Executive Officer (CEO) and was succeeded by Paul M. Bisaro. The company’s international presence began with the acquisition of the Arrow Group in 2009, providing the company with commercial presence in more than 20 international markets. As a result of the Arrow acquisition, the company also acquired the biopharmaceutical development organization Eden Biodesign in Liverpool, UK.
2011 to 2014
In 2011, the company moved its corporate headquarters from Corona, California to Parsippany, New Jersey. The new LEED-certified corporate headquarters at the Morris Corporate Center in Parsippany was formally dedicated on June 9, 2011.
Actavis Acquisition and Watson Name Change
In November 2012, Watson acquired the Switzerland-based, global generics company Actavis Group for EUR4.25 billion, creating the world’s third largest generics company, with a leading position in key established commercial markets including the U.S., UK, Nordics, Canada, Australia, and emerging markets in Central and Eastern Europe, and Russia. Following the acquisition, Watson adopted Actavis' name for its global operations.
Warner Chilcott plc Acquisition
On October 1, 2013 Actavis acquired Irish pharmaceutical company Warner Chilcott plc (previously known as Galen) in a stock-for-stock transaction valued at approximately $8.5 billion. The combination created a company with approximately $10 billion in anticipated combined annual 2013 revenue, and the third-largest U.S. specialty pharmaceutical company with approximately $3 billion in annual revenue focused on the core therapeutic categories of women’s health, urology, gastroenterology and dermatology. In association with the merger the company relocated its corporate headquarters to Ireland while maintaining its operational headquarters in Parsippany, taking advantage of the lower (17% vs. 35% in the United States) Irish corporate tax rate. This deal inspired a series of similar moves by other drug companies and led to new Treasury Department regulations limiting the ability of companies to perform such inversions, although Actavis was exempt from these regulations as its move abroad had already been completed. CEO Paul Bisaro stated that in making the inversion, they were trying to "level the playing field" given the high corporate tax rate in the United States.
Forest Laboratories Acquisition
On July 1, 2014 Actavis announced that it had completed its acquisition of Forest Laboratories (who previously acquired, Furiex Pharmaceuticals Inc and Aptalis Pharma) in a cash and equity transaction valued at approximately $25 billion. Following the acquisition, the company restructured its executive leadership, with Paul Bisaro being named Executive Chairman, and Brent Saunders being appointed CEO and President of the combined organization.
Allergan, inc Acquisition and Actavis, plc Name Change
In November 2014 Actavis, plc announced its intention to acquire Allergan, inc, the manufacturer of Botox Completion of the deal would increase its market capitalization to $147 billion. On March 17, 2015, Actavis, plc completed the acquisition of Allergan, inc in a cash and equity transaction valued at approximately $70.5 billion. The combination created a $23 billion diversified global pharmaceutical company with commercial reach across 100 countries. In June 2015, Actavis, plc officially changed its name to Allergan, plc.
(formerly known as Actavis until June 2015
when it adopted Allergans name)
Locations and facilities
The company has 40 manufacturing facilities in five continents providing the company with a core leadership position in modified release products, solid oral dosages, transdermals, semi-solids, liquids and injectables. The company’s manufacturing facilities are located in Belgium, Brazil, Bulgaria, Canada, China, France, Germany, Greece, Iceland, India, Indonesia, Ireland, Northern-Ireland, Italy, Malta, Puerto Rico, Romania, Singapore, Serbia, Thailand, UK and USA.
Research and development facilities
Actavis, plc has 27 global R&D facilities focusing on the development of modified release products, solid oral dosages, transdermals, semi-solids, liquids and injectables around the world. The company’s R&D facilities are located in Belgium, Bulgaria, China, France, Iceland, Italy, India, Indonesia, Ireland, Japan, Northern Ireland, Romania, UK and USA.
- "Actavis plc". MarketWatch.
- "Form 10K". Actavis plc.
- "Botox cosmetics". Allergan.
- "Restasis" (PDF). Allergan.
- "Bystolic". Actavis.
- "Juvederm". Allergan.
- "Latisse" (PDF). Allergan.
- "Ozurdex". Allergan.
- "Optive". Allergan.
- "Natrelle". Allergan.
- "Form 10K". Actavis plc.
- "Actavis Confirms Favorable Ruling In Generic Pulmicort RESPULES Patent Suit". First Word Pharma.
- John Carroll. "Can Actavis deliver a promised $6B boost from this pipeline". Fierce Biotech.
- "Actavis Confirms Favorable Ruling In Generic Pulmicort Respules Patent Suit". First Word Pharma.
- Haggerty, Neil (2015-06-15). "Actavis Changes Name to Allergan After Deal for Botox Maker". WSJ. Retrieved 2015-08-07.
- "Allergan Accelerates Transformation to Branded Growth Pharma Leader by Divesting Global Generics Business to Teva for $40.5 Billion" (Press release). Allergan. 27 July 2015. Retrieved 4 December 2015.
- Yoel, Minkoff (27 July 2015). "Teva to buy Allergan Generics for $40.5B". Seeking Alpha. Retrieved 4 December 2015.
- O'Donnell, Carl (3 December 2015). "Teva divesting $1 billion in assets to clear Allergan deal". Reuters. Retrieved 4 December 2015 – via Yahoo! Finance.
- "ACT Profile - Actavis plc Ordinary Shares Stock - Yahoo! Finance". yahoo.com.
- "Watson Pharmaceuticals acquired Arrow Group for 1.75B". TBI.
- "Watson Pharmaceuticals agrees to buy a rival". NY Times. 2000-05-26.
- "WATSON PHARMACEUTICALS TO BUY ANDRX CORP". PharmacyTimes.com.
- "Watson Pharmaceuticals, Inc. Says CEO to Retire, Names Replacement". Fierce Biotech.
- Shannon Pettypiece (2009-06-17). "Watson Agrees to Buy Arrow Group for $1.75 Billion". Bloomberg.[dead link]
- Gareth Macdonald. "Watson buys Eden Biodesign". Biopharma-Reporter.com.
- "Generic drug maker Watson opening research operations in North Brunswick". NJ.com.
- Eyk Henning (2012-04-25). "Watson, Actavis to Merge in €4.5 Billion Deal". Wall Street Journal.
- "News - Actavis". Actavis.
- Loftus, Peter (2013-05-20). "Actavis to Buy Warner Chilcott in $5 Billion Deal". The Wall Street Journal.
- Gelles, David (2014-11-17). "Allergan Escapes Valeant’s Pursuit, Agreeing to Be Bought by Actavis". The New York Times.
- Drew Armstrong (2013-05-21). "Actavis Lowers Tax Rate to 17% After Warner Chilcott Deal". Bloomberg.com.
- Wainer, David (2014-02-18). "Actavis to buy Forest Laboratories for 25 billion". Bloomberg.
- "GEN - News Highlights:Actavis Deal's a Dandy for Activist Icahn". GEN.
- "BBC News - Actavis to buy Botox-maker Allergan $66bn". BBC News.
- Caroline Chen (2014-11-17). "Actavis Surges to Top Drugmaker Ranks With Acquisitions". Bloomberg.com.
- Willhite, James (2014-11-17). "The Morning Ledger: Actavis Could Again Evade Treasury’s Grasp for Post-Inversion Tax Break". WSJ.
- "Actavis plc is now Allergan plc". Retrieved 16 June 2015.
- "Actavis plc". MarketWatch.